[1. Eikelboom JW, Hirsh J, Spencer FA, et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e89S-119S.10.1378/chest.11-2293]Search in Google Scholar
[2. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e637S-68S.10.1378/chest.141.4.1129c]Search in Google Scholar
[3. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (London, England). 2009;373(9678):1849-60.10.1016/S0140-6736(09)60503-1]Search in Google Scholar
[4. Pettersen A a., Arnesen H, Seljeflot I. A brief review on high on-aspirin residual platelet reactivity. Vascul Pharmacol. 2015;67-69:6-9.10.1016/j.vph.2015.03.01825869498]Search in Google Scholar
[5. Pedersen SB, Grove EL, Nielsen HL, et al. Evaluation of aspirin response by Multiplate whole blood aggregometry and light transmission aggregometry. Platelets. 2009;20(6):415-20.10.1080/0953710090310064319658002]Search in Google Scholar
[6. Kovács EG, Katona É, Bereczky Z, et al. Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods. Thromb Res 2014;33(5):811-6.10.1016/j.thromres.2013.10.00824207016]Search in Google Scholar
[7. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2014.10.1161/STROKEAHA.115.00866125744519]Search in Google Scholar
[8. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345(25):1809-17.10.1056/NEJMoa00319911752357]Search in Google Scholar
[9. Fitzgerald DJ, Maree A. Aspirin and clopidogrel resistance. Hematology Am Soc Hematol Educ Program .2007;(1):114-20.10.1182/asheducation-2007.1.11418024618]Search in Google Scholar
[10. Malinin AI, Ong S, Makarov LM, et al. Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int J Clin Pract. 2006;60(8):993-1002.10.1111/j.1742-1241.2006.01063.x16893441]Search in Google Scholar
[11. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet (London, England). 2006;367(9510):606-17.10.1016/S0140-6736(06)68040-9]Search in Google Scholar
[12. Feher G, Koltai K, Papp E, et al. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables. Drugs Aging. 2006;23(7):559-67.10.2165/00002512-200623070-0000216930084]Search in Google Scholar
[13. Uzun F, Biyik I, Akturk IF, et al. Antiplatelet resistance and the role of associated variables in stable patients treated with stenting. Postępy w Kardiol interwencyjnej = Adv Interv Cardiol. 2015;11(1):19-25.10.5114/pwki.2015.49180437262725848366]Search in Google Scholar
[14. Liu X-F, Cao J, Fan L, et al. Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery disease. J Geriatr Cardiol. 2013;10(1):21-7.]Search in Google Scholar
[15. Akoglu H, Agbaht K, Piskinpasa S, et al. High frequency of aspirin resistance in patients with nephrotic syndrome. Nephrol Dial Transplant. 2012;27(4):1460-6.10.1093/ndt/gfr47621865214]Search in Google Scholar
[16. Kameda S, Sakata T, Kokubo Y, et al. Association of platelet aggregation with lipid levels in the Japanese population: the Suita study. J Atheroscler Thromb. 2011;18(7):560-7.10.5551/jat.628821427509]Search in Google Scholar